Ariad Pharmaceuticals (ARIA) 6.15 $ARIA
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene
PR Newswire - Fri Nov 14, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), iBio Inc. (NYSE MKT: IBIO), and Celgene Corporation (NASDAQ: CELG). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, November 13, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,652.79, up 0.23% and the NASDAQ Composite closed at 4,680.14, up 0.11%. The S&P 500 finished the session 0.05% higher at 2,039.33. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.78, down 0.10%, whereas the index has gained 10.85% in the previous three months. Register for your complimentary reports on these five stocks at:
GILD: 102.06 (-2.14), IBIO: 1.05 (-0.03), ARIA: 6.15 (-0.10), MNKD: 6.16 (-0.02), CELG: 104.05 (-3.38)
'Mad Money' Lightning Round: A Group to Avoid
at The Street - Fri Nov 14, 5:00AM CST
Cramer says he's not going against Affymetrix, and doesn't want to get back into the sand game.
DCT: 8.34 (-0.05), CBI: 54.19 (+0.68), FMSA: 12.70 (+0.04), KODK: 22.50 (+0.15), WNR: 41.06 (-1.60), FRT: 131.21 (-0.97), ARIA: 6.15 (-0.10), AFFX: 9.71 (+0.02), ADSK: 59.66 (+0.35)
Cramer's Lightning Round - Affymetrix Teased And Disappointed, But Is A Buy (11/13/14)
SA Editor Miriam Metzinger - Seeking Alpha - Fri Nov 14, 2:40AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday November 13. Bullish Calls: Affymetrix (NASDAQ: AFFX ): "This company has over time teased people and then disappointed them, but I believe...
CBI: 54.19 (+0.68), FMSA: 12.70 (+0.04), KODK: 22.50 (+0.15), WNR: 41.06 (-1.60), FRT: 131.21 (-0.97), ARIA: 6.15 (-0.10), ADSK: 59.66 (+0.35), AFFX: 9.71 (+0.02)
Jim Cramer's 'Mad Money' Recap: Market 'Losers' Back in the Game
at The Street - Thu Nov 13, 5:49PM CST
Some stocks written off by this market are looking better than ever, Cramer says.
FLEX: 11.10 (+0.21), KMB: 112.65 (-1.42), M: 62.05 (+0.48), WMT: 82.96 (+0.02), FLTX: 37.10 (+0.12), AFFX: 9.71 (+0.02), DPS: 70.10 (-0.61), DCT: 8.34 (-0.05), JACK: 71.75 (-0.59), FMSA: 12.70 (+0.04), CSCO: 26.32 (+0.64), CBI: 54.19 (+0.68), KODK: 22.50 (+0.15), DIS: 90.80 (+0.31), WNR: 41.06 (-1.60), FRT: 131.21 (-0.97), BA: 128.86 (+0.33), PLKI: 53.44 (+1.55), AZO: 567.11 (-6.61), JCP: 7.38 (+0.28), JWN: 74.17 (+0.92), ARIA: 6.15 (-0.10), DOW: 51.37 (+1.41), ADSK: 59.66 (+0.35)
ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting
Business Wire - Thu Nov 06, 8:44AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the schedule of several data presentations on Iclusig(R) (ponatinib) that will take place at the 56th Annual Meeting of the American Society of Hematology (ASH) being held in San Francisco, December 6 to 9, 2014. A total of 17 abstracts were accepted at ASH. The schedule and meeting location for key sessions at ASH, together with the abstract information, are listed below:
ARIA: 6.15 (-0.10)
Ariad Pharmaceuticals' (ARIA) CEO Harvey Berger on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 11:47AM CST
ARIA: 6.15 (-0.10)
Ariad updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 8:49AM CST
ARIA: 6.15 (-0.10)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 8:16AM CST
TTPH: 22.61 (-0.61), AWAY: 30.97 (unch), PHMD: 2.40 (+0.07), ROYT: 9.45 (-0.10), VG: 3.75 (+0.03), MEMP: 16.37 (+1.01), MACK: 8.48 (+0.09), ATVI: 20.10 (-0.23), NUS: 39.40 (-0.32), SSYS: 104.85 (+3.74), EOG: 98.16 (+2.31), CLNY: 24.63 (-0.04), CRTO: 39.00 (+0.80), IBIO: 1.05 (-0.03), NICE: 46.42 (+0.02), VPCO: 1.81 (-0.10), ZU: 28.40 (-0.28), EXEL: 1.73 (-0.03), ANV: 1.37 (+0.17), FEYE: 33.80 (+0.46), JIVE: 6.83 (-0.10), TRIP: 69.91 (+0.89), WLT: 2.94 (+0.08), YOD: 2.20 (-0.36), CHUY: 21.77 (-0.48), ANR: 2.60 (+0.18), NG: 2.88 (+0.13), AEZS: 0.56 (-0.03), ARIA: 6.15 (-0.10), CTSH: 53.28 (-0.11)
ARIAD Pharmaceuticals (ARIA) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 7:25AM CST
ARIA: 6.15 (-0.10)
Ariad tops 3Q profit forecasts
Automated Insights - Wed Nov 05, 6:57AM CST
CAMBRIDGE, Mass. (AP) _ Ariad Pharmaceuticals Inc. (ARIA) on Wednesday reported a third-quarter loss of $50.1 million.
ARIA: 6.15 (-0.10)
ARIAD Pharmaceuticals beats by $0.03, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 6:36AM CST
ARIA: 6.15 (-0.10)
ARIAD Reports Third Quarter 2014 Financial Results and Development Progress
Business Wire - Wed Nov 05, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the third quarter of 2014, including revenue from sales of Iclusig(R) (ponatinib). The Company also provided an update on corporate developments.
ARIA: 6.15 (-0.10)
Notable earnings before Wednesday’s open
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:30PM CST
MDLZ: 38.16 (-0.07), CSTE: 59.37 (+0.15), FSS: 15.65 (+0.06), HL: 2.52 (+0.22), BBEP: 15.55 (+0.66), RRD: 16.93 (-0.13), CNP: 24.04 (-0.15), INXN: 28.28 (-0.32), OGE: 36.35 (-0.08), MNTA: 10.63 (+0.09), GLDD: 7.23 (+0.11), AXAS: 4.07 (+0.16), MEMP: 16.37 (+1.01), PWE: 4.22 (+0.16), ROC: 79.19 (+0.46), SSYS: 104.85 (+3.74), DNR: 11.20 (+0.21), MVIS: 1.70 (+0.02), PWR: 33.16 (-0.49), COV: 93.98 (+0.31), SMG: 60.60 (+0.27), SEP: 56.36 (+0.36), CLH: 48.95 (+0.39), ATHM: 44.58 (+1.59), STWD: 23.52 (+0.02), BPI: 11.26 (+0.26), LVLT: 49.04 (+0.40), AVA: 33.46 (-0.45), MGA: 103.92 (+0.53), BSFT: 27.50 (+0.05), EE: 37.55 (-0.18), CTSH: 53.28 (-0.11), DAVE: 25.75 (+0.15), NRG: 31.31 (-0.24), CEQP: 8.46 (-0.12), ACT: 243.77 (+2.14), AWR: 34.24 (-0.21), DUK: 79.11 (+0.12), LAMR: 52.55 (-0.01), CCC: 21.22 (+0.05), HFC: 42.83 (+0.04), RTI: 23.62 (+0.60), CHK: 23.21 (+0.50), NUS: 39.40 (-0.32), NICE: 46.42 (+0.02), HRC: 44.76 (-0.27), ENDP: 66.26 (-0.84), SE: 38.12 (+0.26), CBB: 3.47 (+0.06), GTN: 10.11 (+0.39), ANSS: 79.79 (+0.50), RLGY: 42.97 (+0.37), ENB: 45.37 (-0.07), SBGI: 28.09 (+0.74), ARIA: 6.15 (-0.10), LPX: 14.61 (-0.29), RDC: 23.75 (-0.01), KELYA: 15.42 (+0.01)
Will ARIAD (ARIA) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:00PM CST
ARIAD Pharmaceuticals, Inc. (ARIA) has Earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 88.11 (+1.15), ACT: 243.77 (+2.14), ARIA: 6.15 (-0.10), HSP: 58.28 (+0.19)
ARIAD to Present at the Stifel 2014 Healthcare Conference
Business Wire - Tue Nov 04, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Stifel 2014 Healthcare Conference in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company's business on Tuesday, November 18, 2014 at 10:55 a.m. (ET).
ARIA: 6.15 (-0.10)
CHMP says Iclusig OK to use as is, advises revised label
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 9:26AM CDT
ARIA: 6.15 (-0.10)
ARIAD Announces Adoption of Final Opinion for Iclusig by Committee for Medicinal Products for Human Use in Europe
Business Wire - Fri Oct 24, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted its final opinion on Iclusig(R) (ponatinib) following the recommendations made by the Pharmacovigilance Risk Assessment Committee (PRAC) earlier this month. The PRAC conducted an 11-month review of the available data on Iclusig and consulted with a scientific advisory group in oncology. This week, the EMA recommended that Iclusig continue to be used in accordance with its already approved indications as a treatment of certain leukaemias and confirmed that the benefit-risk profile of Iclusig continues to be positive in each of these indications. The EMA also recommended additional warnings in the European product information to minimize the risk of vascular events.
ARIA: 6.15 (-0.10)
Insider Trading Alerts for Micron, CSX, Ariad Pharmaceuticals, IBM, SinoCoking Coal and Coke Chemical, and MannKind
PR Newswire - Tue Oct 21, 7:55AM CDT
Insiderslab.com, a U.S. market research community with a special focus on updating investors with insider trading news, revealed the latest insider trading alerts for U.S. stock investors, who can access these reports through the links below, including stock performance, insider trading signals, and visual results. The reports cover the stocks of Micron (NASDAQ:MU), CSX (NYSE:CSX), Ariad Pharmaceuticals (NASDAQ:ARIA), International Business Machines (NYSE:IBM), SinoCoking Coal and Coke Chemical (NASDAQ:SCOK), and MannKind (NASDAQ:MNKD).
MU: 32.62 (-0.32), SCOK: 3.29 (+0.15), IBM: 164.16 (+1.37), ARIA: 6.15 (-0.10), MNKD: 6.16 (-0.02), CSX: 36.79 (+0.16)
Insider Trading Research for Halliburton, Ariad Pharmaceuticals, KeyCorp, GoPro, MannKind, and Plug Power
PR Newswire - Mon Oct 20, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Halliburton (NYSE:HAL), Ariad Pharmaceuticals (NASDAQ:ARIA), KeyCorp (NYSE:KEY), GoPro (NASDAQ:GPRO), MannKind (NASDAQ:MNKD), and Plug Power (NASDAQ
LUG).
GPRO: 79.15 (+2.68), PLUG: 3.72 (-0.34), HAL: 55.08 (+1.29), KEY: 13.35 (-0.10), ARIA: 6.15 (-0.10), MNKD: 6.16 (-0.02)
16.9% Return Seen to Date on SmarTrend Ariad Pharmaceuticals Call (ARIA)
Comtex SmarTrend(R) - Wed Oct 15, 9:32AM CDT
SmarTrend identified a Downtrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 8th, 2014 at $6.07. In approximately 3 months, Ariad Pharmaceuticals has returned 16.90% as of today's recent price of $5.04.
ARIA: 6.15 (-0.10)
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene
PR Newswire - Fri Nov 14, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), iBio Inc. (NYSE MKT: IBIO), and Celgene Corporation (NASDAQ: CELG). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, November 13, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,652.79, up 0.23% and the NASDAQ Composite closed at 4,680.14, up 0.11%. The S&P 500 finished the session 0.05% higher at 2,039.33. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.78, down 0.10%, whereas the index has gained 10.85% in the previous three months. Register for your complimentary reports on these five stocks at:
GILD: 102.06 (-2.14), IBIO: 1.05 (-0.03), ARIA: 6.15 (-0.10), MNKD: 6.16 (-0.02), CELG: 104.05 (-3.38)
'Mad Money' Lightning Round: A Group to Avoid
at The Street - Fri Nov 14, 5:00AM CST
Cramer says he's not going against Affymetrix, and doesn't want to get back into the sand game.
DCT: 8.34 (-0.05), CBI: 54.19 (+0.68), FMSA: 12.70 (+0.04), KODK: 22.50 (+0.15), WNR: 41.06 (-1.60), FRT: 131.21 (-0.97), ARIA: 6.15 (-0.10), AFFX: 9.71 (+0.02), ADSK: 59.66 (+0.35)
Cramer's Lightning Round - Affymetrix Teased And Disappointed, But Is A Buy (11/13/14)
SA Editor Miriam Metzinger - Seeking Alpha - Fri Nov 14, 2:40AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday November 13. Bullish Calls: Affymetrix (NASDAQ: AFFX ): "This company has over time teased people and then disappointed them, but I believe...
CBI: 54.19 (+0.68), FMSA: 12.70 (+0.04), KODK: 22.50 (+0.15), WNR: 41.06 (-1.60), FRT: 131.21 (-0.97), ARIA: 6.15 (-0.10), ADSK: 59.66 (+0.35), AFFX: 9.71 (+0.02)
Jim Cramer's 'Mad Money' Recap: Market 'Losers' Back in the Game
at The Street - Thu Nov 13, 5:49PM CST
Some stocks written off by this market are looking better than ever, Cramer says.
FLEX: 11.10 (+0.21), KMB: 112.65 (-1.42), M: 62.05 (+0.48), WMT: 82.96 (+0.02), FLTX: 37.10 (+0.12), AFFX: 9.71 (+0.02), DPS: 70.10 (-0.61), DCT: 8.34 (-0.05), JACK: 71.75 (-0.59), FMSA: 12.70 (+0.04), CSCO: 26.32 (+0.64), CBI: 54.19 (+0.68), KODK: 22.50 (+0.15), DIS: 90.80 (+0.31), WNR: 41.06 (-1.60), FRT: 131.21 (-0.97), BA: 128.86 (+0.33), PLKI: 53.44 (+1.55), AZO: 567.11 (-6.61), JCP: 7.38 (+0.28), JWN: 74.17 (+0.92), ARIA: 6.15 (-0.10), DOW: 51.37 (+1.41), ADSK: 59.66 (+0.35)
ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting
Business Wire - Thu Nov 06, 8:44AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the schedule of several data presentations on Iclusig(R) (ponatinib) that will take place at the 56th Annual Meeting of the American Society of Hematology (ASH) being held in San Francisco, December 6 to 9, 2014. A total of 17 abstracts were accepted at ASH. The schedule and meeting location for key sessions at ASH, together with the abstract information, are listed below:
ARIA: 6.15 (-0.10)
Ariad Pharmaceuticals' (ARIA) CEO Harvey Berger on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 11:47AM CST
ARIA: 6.15 (-0.10)
Ariad updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 8:49AM CST
ARIA: 6.15 (-0.10)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 8:16AM CST
TTPH: 22.61 (-0.61), AWAY: 30.97 (unch), PHMD: 2.40 (+0.07), ROYT: 9.45 (-0.10), VG: 3.75 (+0.03), MEMP: 16.37 (+1.01), MACK: 8.48 (+0.09), ATVI: 20.10 (-0.23), NUS: 39.40 (-0.32), SSYS: 104.85 (+3.74), EOG: 98.16 (+2.31), CLNY: 24.63 (-0.04), CRTO: 39.00 (+0.80), IBIO: 1.05 (-0.03), NICE: 46.42 (+0.02), VPCO: 1.81 (-0.10), ZU: 28.40 (-0.28), EXEL: 1.73 (-0.03), ANV: 1.37 (+0.17), FEYE: 33.80 (+0.46), JIVE: 6.83 (-0.10), TRIP: 69.91 (+0.89), WLT: 2.94 (+0.08), YOD: 2.20 (-0.36), CHUY: 21.77 (-0.48), ANR: 2.60 (+0.18), NG: 2.88 (+0.13), AEZS: 0.56 (-0.03), ARIA: 6.15 (-0.10), CTSH: 53.28 (-0.11)
ARIAD Pharmaceuticals (ARIA) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 7:25AM CST
ARIA: 6.15 (-0.10)
Ariad tops 3Q profit forecasts
Automated Insights - Wed Nov 05, 6:57AM CST
CAMBRIDGE, Mass. (AP) _ Ariad Pharmaceuticals Inc. (ARIA) on Wednesday reported a third-quarter loss of $50.1 million.
ARIA: 6.15 (-0.10)
ARIAD Pharmaceuticals beats by $0.03, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 6:36AM CST
ARIA: 6.15 (-0.10)
ARIAD Reports Third Quarter 2014 Financial Results and Development Progress
Business Wire - Wed Nov 05, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the third quarter of 2014, including revenue from sales of Iclusig(R) (ponatinib). The Company also provided an update on corporate developments.
ARIA: 6.15 (-0.10)
Notable earnings before Wednesday’s open
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:30PM CST
MDLZ: 38.16 (-0.07), CSTE: 59.37 (+0.15), FSS: 15.65 (+0.06), HL: 2.52 (+0.22), BBEP: 15.55 (+0.66), RRD: 16.93 (-0.13), CNP: 24.04 (-0.15), INXN: 28.28 (-0.32), OGE: 36.35 (-0.08), MNTA: 10.63 (+0.09), GLDD: 7.23 (+0.11), AXAS: 4.07 (+0.16), MEMP: 16.37 (+1.01), PWE: 4.22 (+0.16), ROC: 79.19 (+0.46), SSYS: 104.85 (+3.74), DNR: 11.20 (+0.21), MVIS: 1.70 (+0.02), PWR: 33.16 (-0.49), COV: 93.98 (+0.31), SMG: 60.60 (+0.27), SEP: 56.36 (+0.36), CLH: 48.95 (+0.39), ATHM: 44.58 (+1.59), STWD: 23.52 (+0.02), BPI: 11.26 (+0.26), LVLT: 49.04 (+0.40), AVA: 33.46 (-0.45), MGA: 103.92 (+0.53), BSFT: 27.50 (+0.05), EE: 37.55 (-0.18), CTSH: 53.28 (-0.11), DAVE: 25.75 (+0.15), NRG: 31.31 (-0.24), CEQP: 8.46 (-0.12), ACT: 243.77 (+2.14), AWR: 34.24 (-0.21), DUK: 79.11 (+0.12), LAMR: 52.55 (-0.01), CCC: 21.22 (+0.05), HFC: 42.83 (+0.04), RTI: 23.62 (+0.60), CHK: 23.21 (+0.50), NUS: 39.40 (-0.32), NICE: 46.42 (+0.02), HRC: 44.76 (-0.27), ENDP: 66.26 (-0.84), SE: 38.12 (+0.26), CBB: 3.47 (+0.06), GTN: 10.11 (+0.39), ANSS: 79.79 (+0.50), RLGY: 42.97 (+0.37), ENB: 45.37 (-0.07), SBGI: 28.09 (+0.74), ARIA: 6.15 (-0.10), LPX: 14.61 (-0.29), RDC: 23.75 (-0.01), KELYA: 15.42 (+0.01)
Will ARIAD (ARIA) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:00PM CST
ARIAD Pharmaceuticals, Inc. (ARIA) has Earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 88.11 (+1.15), ACT: 243.77 (+2.14), ARIA: 6.15 (-0.10), HSP: 58.28 (+0.19)
ARIAD to Present at the Stifel 2014 Healthcare Conference
Business Wire - Tue Nov 04, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Stifel 2014 Healthcare Conference in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company's business on Tuesday, November 18, 2014 at 10:55 a.m. (ET).
ARIA: 6.15 (-0.10)
CHMP says Iclusig OK to use as is, advises revised label
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 9:26AM CDT
ARIA: 6.15 (-0.10)
ARIAD Announces Adoption of Final Opinion for Iclusig by Committee for Medicinal Products for Human Use in Europe
Business Wire - Fri Oct 24, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted its final opinion on Iclusig(R) (ponatinib) following the recommendations made by the Pharmacovigilance Risk Assessment Committee (PRAC) earlier this month. The PRAC conducted an 11-month review of the available data on Iclusig and consulted with a scientific advisory group in oncology. This week, the EMA recommended that Iclusig continue to be used in accordance with its already approved indications as a treatment of certain leukaemias and confirmed that the benefit-risk profile of Iclusig continues to be positive in each of these indications. The EMA also recommended additional warnings in the European product information to minimize the risk of vascular events.
ARIA: 6.15 (-0.10)
Insider Trading Alerts for Micron, CSX, Ariad Pharmaceuticals, IBM, SinoCoking Coal and Coke Chemical, and MannKind
PR Newswire - Tue Oct 21, 7:55AM CDT
Insiderslab.com, a U.S. market research community with a special focus on updating investors with insider trading news, revealed the latest insider trading alerts for U.S. stock investors, who can access these reports through the links below, including stock performance, insider trading signals, and visual results. The reports cover the stocks of Micron (NASDAQ:MU), CSX (NYSE:CSX), Ariad Pharmaceuticals (NASDAQ:ARIA), International Business Machines (NYSE:IBM), SinoCoking Coal and Coke Chemical (NASDAQ:SCOK), and MannKind (NASDAQ:MNKD).
MU: 32.62 (-0.32), SCOK: 3.29 (+0.15), IBM: 164.16 (+1.37), ARIA: 6.15 (-0.10), MNKD: 6.16 (-0.02), CSX: 36.79 (+0.16)
Insider Trading Research for Halliburton, Ariad Pharmaceuticals, KeyCorp, GoPro, MannKind, and Plug Power
PR Newswire - Mon Oct 20, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Halliburton (NYSE:HAL), Ariad Pharmaceuticals (NASDAQ:ARIA), KeyCorp (NYSE:KEY), GoPro (NASDAQ:GPRO), MannKind (NASDAQ:MNKD), and Plug Power (NASDAQ
LUG). GPRO: 79.15 (+2.68), PLUG: 3.72 (-0.34), HAL: 55.08 (+1.29), KEY: 13.35 (-0.10), ARIA: 6.15 (-0.10), MNKD: 6.16 (-0.02)
16.9% Return Seen to Date on SmarTrend Ariad Pharmaceuticals Call (ARIA)
Comtex SmarTrend(R) - Wed Oct 15, 9:32AM CDT
SmarTrend identified a Downtrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 8th, 2014 at $6.07. In approximately 3 months, Ariad Pharmaceuticals has returned 16.90% as of today's recent price of $5.04.
ARIA: 6.15 (-0.10)
